Despite its acceptance as standard of care neary 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), according to research presented at the ASCO 2014 Breast Cancer Symposium.
Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.
Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.
Patients with non-small cell lung cancer and resistance to gefitinib do not experience any significant improvement with gefitinib.
Drug should remain standard of care for HER2-positive tumors, according to new research.
Aspirin and other other NSAIDs were associated with a decreased risk for developing an aggressive form of prostate cancer.
This fact sheet explores the evidence that tea consumption may aid cancer prevention.
This fact sheet examines the potential pros and cons of surgery as a means to reduce breast cancer risk.
Ann J. Brady, MSN, RN-BC
Jia Conway, DNP, FNP-BC, AOCNP, NP-C
Michele M. Farrington, BSN, RN, CPHON
Donald R. Fleming, MD
Arati Jairam-Thodla, MSN, CNP
Karen MacDonald, RN, BSN, CPON
Marlene McGuire, RN, MA, ANP-C
Kerstin L. McSteen, BSN, MSN, ACHPN, CNS-BC
Helen H. Miller, LCSW, ACSW
Maribel Pereiras, PharmD, BCPS, BCOP
Leah A. Scaramuzzo, MSN, RN-BC, AOCN
Lisa A. Thompson, PharmD, BCOP
Rosemarie A. Tucci, RN, MSN, AOCN
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|